Like the Wood Group, Alexion, an American pharmaceutical company, has disclosed preliminary discussions with the SEC to resolve a cross-border bribery investigation involving Brazil, Russia, Turkey, and Japan. U.S. authorities started investigating Alexion in 2015 when the SEC requested information about Alexion's grant-making activities, as well as its compliance with the FCPA in those jurisdictions, which the U.S. DOJ has also questioned. [xviii] A bit later, in 2017, Brazilian authorities raided Alexion's office in São Paulo in connection with the U.S. investigations. [xix]